BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND STAG2, RP11-517O1_1, 10735, ENSG00000101972, DKFZp781H1753, SA2, SA-2, FLJ25871, DKFZp686P168, bA517O1_1 AND Treatment
11992 results:

  • 1. Cancer treatment Before and After Physician-Pharmacy Integration.
    Kanter GP; Ozluk P; Chi W; Fisch MJ; Debono D; Parikh RB; Jacobson M; Bekelman JE; DeVries A
    JAMA Netw Open; 2024 May; 7(5):e2412998. PubMed ID: 38780938
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study.
    Hai L; Liu S; Ma L; Ding X; Bai X; Luo X
    Technol Cancer Res Treat; 2024; 23():15330338241250315. PubMed ID: 38773767
    [No Abstract]    [Full Text] [Related]  

  • 3. Disparities in treatment patterns and mortality in prostate cancer: Interaction between Black race and end-stage kidney disease.
    Sarabu N; Dong W; Koroukian SM
    Cancer Med; 2024 May; 13(10):e7027. PubMed ID: 38770622
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib.
    Lin Z; Xiao S; Qi Y; Guo J; Lu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
    Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
    BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. End-stage renal disease after renal cancer surgery: risk factors and overall survival.
    Åkerlund J; Ljungberg B; Lundstam S; Peeker R; Holmberg E; Månsson M; Grenabo Bergdahl A
    Scand J Urol; 2024 May; 59():109-116. PubMed ID: 38747153
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Endoscopic intervention versus radical nephroureterectomy for the management of localized upper urinary tract urothelial carcinoma: a systematic review and meta-analysis of comparative studies.
    Giulioni C; Brocca C; Tramanzoli P; Stramucci S; Mantovan M; Perpepaj L; Cicconofri A; Gauhar V; Merseburger AS; Galosi AB; Castellani D
    World J Urol; 2024 May; 42(1):318. PubMed ID: 38743260
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Single-layer versus double-layer renorrhaphy technique during robot-assisted partial nephrectomy: impact on perioperative outcomes, complications, and functional outcomes.
    Bertolo R; Ditonno F; Veccia A; DE Marco V; Migliorini F; Porcaro AB; Rizzetto R; Cerruto MA; Autorino R; Antonelli A
    Minerva Urol Nephrol; 2024 Apr; 76(2):176-184. PubMed ID: 38742552
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Acute Airway Obstruction: An Unusual Presentation of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Recipient.
    Aggarwal J; Kumar DJ; Rathore V; Mehta R; Kumar A; Ravina M
    Exp Clin Transplant; 2024 Apr; 22(4):307-310. PubMed ID: 38742322
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Seven oral traditional Chinese medicine combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis.
    Liu K; Li Q; Lu X; Fan X; Yang Y; Xie W; Kang J; Sun S; Zhao J
    Pharm Biol; 2024 Dec; 62(1):404-422. PubMed ID: 38739082
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. CircPRELID2 functions as a promoter of renal cell carcinoma through the miR-22-3p/ETV1 cascade.
    Lin X; Zhi Y
    BMC Urol; 2024 May; 24(1):104. PubMed ID: 38730434
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
    Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
    BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
    Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
    J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Microsurgical reconstruction for head and neck in patients with end-stage renal disease undergoing dialysis.
    Hung CT; Wu MS; Wang CH; Cheng LF; Chou YF; Lee CF; Chen PR; Lee JT
    Microsurgery; 2024 May; 44(4):e31186. PubMed ID: 38716649
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. CXCR2/Snail-1-Induced Epithelial-Mesenchymal Transition in the Formation and Progression of RCC with Inferior Vena Cava Tumour Thrombus.
    Wang L; Gao J; Zheng S; Luo Z; Xu Z; Che H; Wang Z
    Arch Esp Urol; 2024 Apr; 77(3):292-302. PubMed ID: 38715171
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
    Uhlig J; Uhlig A; Deshpande H; Ströbel P; Trojan L; Lotz J; Hurwitz M; Hafez O; Humphrey P; Grünwald V; Kim HS
    Sci Rep; 2024 May; 14(1):10038. PubMed ID: 38693188
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A retrospective clinical analysis of 11 cases of PEComa from different sites.
    Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
    World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
    Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
    JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal.
    Lendínez-Cano G; Vilches-Arenas Á; Congregado-Ruíz B; Medina-López R
    World J Urol; 2024 Apr; 42(1):267. PubMed ID: 38678165
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 600.